A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2.

Liu J, Pham PT, Skripnikova EV, Zheng S, Lovings LJ, Wang Y, Goyal N, Bellow SM, Mensah LM, Chatters AJ, Bratton MR, Wiese TE, Zhao M, Wang G, Foroozesh M. A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2. J Med Chem. 2015 Aug 27; 58(16):6481-93.

View in: PubMed

subject areas

Cell Line, Tumor
Coumarins
Cytochrome P-450 CYP1A2
Cytochrome P-450 Enzyme System
Drug Design
Humans
Kinetics
Ligands
Models, Chemical
Receptors, Aryl Hydrocarbon
Structure-Activity Relationship

authors with profiles

Maryam Foroozesh
Elena V. Skripnikova
Thomas E. Wiese
Guangdi Wang

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support